Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spigel

Showing results (11-20 of 220) with videos related to

Pageof 22
Sort By:
Clinical Lung Cancer|May 8, 2009
What is the role of novel taxanes in non-small-cell lung cancer?David R Spigel, F Anthony Greco
The Oncologist|June 30, 2016
The Future of Immunotherapy in the Treatment of Small Cell Lung CancerLeora Horn, Martin Reck, David R Spigel
The New England Journal of Medicine|February 10, 2021
Atezolizumab for PD-L1-Selected Patients with NSCLC. ReplyRoy S Herbst, Hiroshi Kuriki, David R Spigel
JAMA|September 24, 2004
Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer historyHarvey J Murff, David R Spigel, Sapna Syngal
Journal of Hepatology|October 7, 2004
Waldenstrom's macroglobulinemia presenting as new-onset ascitesElena Martinez Stoffel, David R Spigel, Norman D Grace
Seminars in Oncology|January 31, 2009
Neuroendocrine carcinoma of unknown primary siteDavid R Spigel, John D Hainsworth, F Anthony Greco
Cancer|April 29, 2008
Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancerDavid R Spigel, Ming Lin, Vincent O'Neill, et al.
International Journal of Oncology|November 5, 2015
Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)Ralph Zinner, Carla Visseren-Grul, David R Spigel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network StudyJohn D Hainsworth, David R Spigel, Sharlene Litchy, et al.
Journal of the National Cancer Institute|May 4, 2013
Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathologyF Anthony Greco, Wayne J Lennington, David R Spigel, et al.
Pageof 22

Showing results (11-20 of 220) with videos related to

Sort By:
Pageof 22
Clinical Lung Cancer|May 8, 2009
What is the role of novel taxanes in non-small-cell lung cancer?David R Spigel, F Anthony Greco
The Oncologist|June 30, 2016
The Future of Immunotherapy in the Treatment of Small Cell Lung CancerLeora Horn, Martin Reck, David R Spigel
The New England Journal of Medicine|February 10, 2021
Atezolizumab for PD-L1-Selected Patients with NSCLC. ReplyRoy S Herbst, Hiroshi Kuriki, David R Spigel
JAMA|September 24, 2004
Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer historyHarvey J Murff, David R Spigel, Sapna Syngal
Journal of Hepatology|October 7, 2004
Waldenstrom's macroglobulinemia presenting as new-onset ascitesElena Martinez Stoffel, David R Spigel, Norman D Grace
Seminars in Oncology|January 31, 2009
Neuroendocrine carcinoma of unknown primary siteDavid R Spigel, John D Hainsworth, F Anthony Greco
Cancer|April 29, 2008
Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancerDavid R Spigel, Ming Lin, Vincent O'Neill, et al.
International Journal of Oncology|November 5, 2015
Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)Ralph Zinner, Carla Visseren-Grul, David R Spigel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network StudyJohn D Hainsworth, David R Spigel, Sharlene Litchy, et al.
Journal of the National Cancer Institute|May 4, 2013
Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathologyF Anthony Greco, Wayne J Lennington, David R Spigel, et al.
Pageof 22